Skip to main content

Table 4 Most Frequently Reported Adverse Events

From: A multicenter, randomized, double-blind study comparing different FK778 doses (manitimus) with tacrolimus and steroids vs. MMF with tacrolimus and steroids in renal transplantation

 

High level FK778

Mid level FK778

Low level FK77

MMF

N = 87

N = 92

N = 92

N = 93

Anemia

37 (42.5)

42 (45.7)

36 (39.1)

35 (37.6)

Leukopenia

7 (8)

11 (12)

6 (6.5)

13 (14)

Thrombocytopeniaa

9 (10.3)

4 (4.3)

11 (12)

2 (2.2)

Diarrhea

14 (16.1)

20 (21.7)

16 (17.4)

23 (24.7)

Constipation

15 (17.2)

8 (8.7)

7 (7.6)

17 (18.3)

Nausea

9 (10.3)

5 (5.4)

6 (6.5)

9 (9.7)

Vomiting

11 (12.6)

12 (13)

7 (7.6)

11 (11.8)

Peripheral edema

13 (14.9)

17 (18.5)

15 (16.3)

12 (12.9)

Chest painb

9 (10.3)

2 (2.2)

2 (2.2)

2 (2.2)

Bacterial urinary tract infection

19 (21.8)

29 (31.5)

28 (30.4)

27 (29)

Cytomegalovirus infection

4 (4.6)

5 (5.4)

9 (9.8)

10 (10.8)

Hypocalcaemia

13 (14.9)

13 (14.1)

12 (13)

9 (9.7)

Hyperglycemia

11 (12.6)

15 (16.3)

10 (10.9)

10 (10.8)

Hyperlipidemia

5 (5.7)

4 (4.3)

2 (2.2)

11 (11.8)

Hypokalemia

15 (17.2)

10 (10.9)

12 (13)

7 (7.5)

Hypoalbuminemiac

5 (5.7)

0

1 (1.1)

0

Hyperuricemia

9 (10.3)

21 (22.8)

20 (21.7)

12 (12.9)

Headache

11 (12.6)

11 (12)

9 (9.8)

4 (4.3)

Tremor

9 (10.3)

12 (13)

9 (9.8)

14 (15.1)

Insomnia

4 (4.6)

3 (3.3)

4 (4.3)

10 (10.8)

Hypertension

20 (23)

16 (17.4)

20 (21.7)

25 (26.9)

  1. Data shown are for the ITT and presented as number (%). Most frequently reported adverse events occurring in ≥10% of patients in any group or occurring with a significant difference between groups. Excluded are renal- and allograft-related adverse events.
  2. a P = 0.02, Fisher’s exact test: high level FK778 vs. MMF; b P = 0.03, Fisher’s exact test: high level FK778 vs. MMF; c P = 0.03, Fisher’s exact test: high level FK778 vs. MMF.